证券代码：688161 证券简称：威高骨科 公告编号：2023-025 山东威高骨科材料股份有限公司 关于公司董事长提议公司回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到公司董事长弓剑波先生《关于提议山东威高骨科材料股份有限公司回购公 司股份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 公司董事长弓剑波先生基于对公司未来持续发展的信心和对公司价值的认 可，为了维护广大投资者利益，增强投资者对公司的投资信心，提高公司员工凝 聚力，增强公司员工的积极性，同时促进公司长期稳定健康发展，有效地将股东 利益、公司利益和员工个人利益紧密结合在一起，提议公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机全部用 于员工持股计划和股权激励计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A 股）。 2、回购股份的用途：用于员工持股及/或股权激励计划。若公司未能 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥389,781,832.60, representing a year-on-year increase of 0.57% compared to ¥387,574,619.74 in the same period last year[6]. - Net profit attributable to shareholders was ¥94,138,278.36, a decrease of 18.11% from ¥114,953,718.82 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥91,026,500.35, down 19.31% from ¥112,803,321.51 in the previous year[6]. - The company reported a basic and diluted earnings per share of ¥0.24, a decrease of 17.24% from ¥0.29 in the same period last year[19]. - Net profit for Q1 2023 was RMB 94,089,505.89, a decrease of 18.2% from RMB 114,908,534.45 in Q1 2022[54]. - The basic earnings per share for Q1 2023 was RMB 0.24, down from RMB 0.29 in Q1 2022[54]. Cash Flow and Liquidity - The net cash generated from operating activities was ¥33,368,877.54, down 81.60% from ¥181,308,485.82 in the same period last year[6]. - Cash inflow from operating activities for Q1 2023 was $495,753,784.36, a decrease of 12.8% compared to $568,437,515.99 in Q1 2022[56]. - Net cash flow from operating activities was $33,368,877.54, down 81.6% from $181,308,485.82 in the same period last year[56]. - Cash outflow from operating activities increased to $462,384,906.82, up 19.4% from $387,129,030.17 in Q1 2022[56]. - Cash and cash equivalents at the end of Q1 2023 were $2,049,281,131.87, down from $2,742,430,707.67 at the end of Q1 2022[57]. - The company reported a significant increase in cash paid for purchasing goods and services, which rose to $104,744,099.73 from $58,210,369.65 in Q1 2022[56]. - The company’s cash flow from other operating activities decreased to $21,584,208.94 from $70,658,125.78 in Q1 2022, highlighting a decline in ancillary income sources[56]. Research and Development - R&D investment totaled ¥27,331,141.04, which is 7.01% of operating revenue, an increase of 1.83 percentage points compared to the previous year[19]. - R&D investment increased by 36.21%, indicating a significant rise in technology development efforts[41]. - Research and development expenses increased to RMB 27,331,141.04 in Q1 2023, compared to RMB 20,064,957.67 in Q1 2022, reflecting a growth of 36.4%[54]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,431,681,083.51, a decrease of 9.70% from the previous year[19]. - The total assets decreased from 6,015,055,250.84 to 5,431,681,083.51, representing a decline of approximately 9.7%[30]. - The total current assets decreased from 5,248,998,758.00 to 4,674,642,163.22, a reduction of about 10.9%[30]. - The total liabilities as of March 31, 2023, were RMB 1,361,102,469.75, an increase from RMB 1,008,842,421.97 as of December 31, 2022[52]. - The company's total equity decreased to RMB 4,070,578,613.76 as of March 31, 2023, down from RMB 5,006,212,828.87 at the end of 2022[52]. - The equity attributable to shareholders decreased by 18.69% due to the acquisition of a subsidiary under common control, which reduced the capital reserve[41]. Business Development and Strategy - The company launched new products, including the "PEEK cranial plate" and "absorbable interface screws," enhancing its offerings in neurosurgery and sports medicine[26][27]. - The company is transforming its sales model to improve terminal surgical volumes by establishing a nationwide logistics distribution network[26]. - The company is expanding into new business areas in orthopedics, particularly in sports medicine and neurosurgery, to support ongoing development[45]. - The company is leveraging its advantages in production lines and brand diversity to enhance market share amid centralized procurement initiatives[45]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[54].

证券代码：688161 证券简称：威高骨科 公告编号：2023-016 山东威高骨科材料股份有限公司 会议召开时间：2023 年 4 月 28 日（星期五）上午 09:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 21 日（星期五）至 4 月 27 日（星期四）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@wegortho.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 （一） 会议召开时间：2023 年 4 月 28 日上午 09:00-11:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 董事长：弓剑波 总经理：卢均强 董事会秘书：林青 财务总监：辛文智 独立董事：曲国霞 （如有特殊情况，参会人员将可能进行调整） 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 ...

Financial Performance - The company achieved operating revenue of 1,848.12 million yuan, a year-on-year decrease of 14.18%[17] - The net profit attributable to shareholders was 544.21 million yuan, down 21.17% year-on-year[17] - The company's operating revenue decreased by RMB 305.43 million, a decline of 14.18%, primarily due to cautious purchasing by distributors influenced by volume-based procurement[35] - The net cash flow from operating activities decreased by RMB 344.71 million, a decline of 43.73%, attributed to the reduction in operating revenue[35] - The company's operating revenue for the reporting period was 184.81 million yuan, a year-on-year decrease of 14.18%, primarily due to the impact of volume-based procurement policies[83] - The gross profit margin for trauma products decreased by 31.57%, primarily due to centralized procurement and a decline in terminal prices[108] - The company reported a net cash flow from operating activities of ¥443,538,409.59, a decrease of 43.73% from ¥788,251,164.57 in the previous year[104] - The net cash flow from investment activities improved by 85.97%, from -¥1,187,980,405.02 to -¥166,636,119.74[139] - The net cash flow from financing activities decreased significantly by 116.89%, from ¥1,353,615,047.31 to -¥228,675,762.62[139] Market Position and Product Development - In the spine sector, the company reported a total of approximately 141,000 units, maintaining the industry’s leading position, with all products successfully bid in the national procurement[18] - The trauma sector saw a total of approximately 266,000 units reported, further increasing market share[18] - The company’s joint brands achieved a surgical demand of about 52,000 units, accounting for 9% of the national procurement demand, with a 36.8% increase compared to pre-procurement surgical volumes[18] - The company is actively exploring new business lines and improving its product offerings in orthopedic rehabilitation and minimally invasive surgical equipment[19] - The company has established a presence in over 3,500 hospitals nationwide, indicating a strong market penetration and competitive positioning[56] - The company is focusing on the orthopedic implant medical device sector and aims to become a leading supplier of orthopedic consumables solutions globally[147] - The implementation of national volume-based procurement has led to significant changes in the industry landscape, with domestic brands gaining market share[159] Research and Development - The company is advancing over 100 research projects in new materials and technologies, including breakthroughs in new bone cement and biodegradable magnesium alloys[19] - The company achieved a total R&D investment of ¥107,766,860.12, a decrease of 11.10% compared to the previous year[64] - R&D investment accounted for 5.83% of total revenue, an increase of 0.2 percentage points from the previous year[64] - The company has obtained 13 Class I product filing certificates, 4 Class II medical device registration certificates, and 28 Class III medical device registration certificates during the reporting period[63] - The company holds 51 domestic and 2 international invention patents, along with 232 Class I product records and 97 Class III medical device registrations, indicating a strong R&D capability[69] - The company applied for a total of 45 patents during the reporting period, with 49 patents granted, bringing the cumulative total to 400 patents[84] Technology and Innovation - The company is implementing a digital factory strategy focused on lean production, automation, and digitalization to enhance production efficiency and cost control[20] - The company has developed a semi-open elastic arm for minimally invasive surgery, which reduces incision size to 13mm, minimizing tissue damage and improving recovery time[46] - The integrated mixing and injection technology for bone cement significantly reduces the release of irritating odors and simplifies the operational process, enhancing efficiency[46] - The locking bone fixation technology allows for stable fixation of fractures without relying on bone friction, improving blood circulation and recovery[47] - The intramedullary nail system reduces infection rates and preserves blood supply to the bone, facilitating quicker recovery for patients[47] - The development of 3D printing technology enhances surgical precision and meets the demand for personalized orthopedic implants[56] - The focus on biodegradable materials for orthopedic implants is expected to become a new profit growth point for the company[56] Strategic Partnerships and Collaborations - The company has established a strategic partnership with Beijing Tianzhihang Medical Technology Co., Ltd. for the development and application of orthopedic surgical robots, aiming to create next-generation orthopedic products suitable for robotic operations[42] - The company has established partnerships with over 2,000 distributors, covering more than 3,500 medical institutions nationwide, enhancing market reach[70] Operational Efficiency and Management - The marketing management department is enhancing sales service levels through timely updates and analysis of customer and sales data[18] - The company is actively pursuing lean production and digital transformation to mitigate risks associated with price declines due to national procurement policies[78] - The company plans to enhance its warehouse management platform and establish a big data center to improve production and sales data integration[99] - The company is integrating its distributor resources and implementing classified management to adapt to the volume-based procurement environment[97] - The company has established a comprehensive quality management system and has obtained ISO9001 and ISO13485 certifications, ensuring product reliability and stability[91] Human Resources and Corporate Governance - The total number of employees in the parent company is 1,613, with a total of 2,047 employees across the parent and major subsidiaries[195] - The company has a total of 1,099 production personnel, 553 sales personnel, 262 technical personnel, 52 financial personnel, and 81 administrative personnel[196] - The company has established a compensation incentive system to ensure the motivation, fairness, and competitiveness of salaries, enhancing employee engagement and creativity[197] - The company conducts targeted training programs for different teams, focusing on improving management quality and leadership skills[198] - The company has implemented a performance management system to clarify performance responsibilities and assessment indicators for all levels of staff[197] - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among various governance bodies[169] Future Outlook and Growth Strategies - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product portfolio[181] - The company plans to expand its operations into new international markets, targeting a 20% increase in overseas sales by the end of the fiscal year[181] - The company has launched a new line of orthopedic implants, which is expected to contribute an additional $50 million in revenue over the next year[181] - The company is focusing on enhancing its digital health solutions, aiming for a 30% increase in user engagement through new technology[181] - The company has set a performance guidance of 10-12% revenue growth for the upcoming fiscal year, reflecting its optimistic outlook[181] - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 25% over the next five years[181]

| --- | --- | |---------------------------------------------------------------------------------------------|-------| | | | | 股票代码: 688161 | | | 山东威高骨科材料股份有限公司 shandong weigao orthopaedic device co., ltd 2022年第三季度报告 | | 2022 年第三季度报告 单位：元 币种：人民币 证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审 ...

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 1,105,226,286.15, a year-on-year increase of 0.90% compared to RMB 1,095,315,818.33 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was RMB 397,978,394.23, reflecting a year-on-year growth of 7.81% from RMB 369,150,481.23[21]. - The net cash flow from operating activities decreased by 10.78%, amounting to RMB 363,815,020.95, down from RMB 407,784,522.96 in the previous year[21]. - The total assets as of June 30, 2022, were RMB 5,753,044,252.81, representing a 6.47% increase from RMB 5,403,274,095.25 at the end of the previous year[23]. - The company's net assets attributable to shareholders increased by 4.22% to RMB 4,722,837,010.78 from RMB 4,531,539,606.55 at the end of the previous year[21]. - Basic earnings per share for the first half of 2022 were RMB 0.99, a decrease of 3.88% compared to RMB 1.03 in the same period last year[24]. - The overall gross profit margin for the reporting period was 78.37%[33]. Research and Development - The R&D investment as a percentage of operating revenue increased by 0.40 percentage points to 5.06%[24]. - R&D expenses totaled ¥55,926,269.02, an increase of 9.68% compared to ¥50,991,443.15 from the previous year[55]. - The company has 264 R&D personnel, representing 12.85% of total employees, an increase from 12.00% last year[62]. - The company has established a complete, independent, and mature R&D technology system in the orthopedic implant field, demonstrating its capability for innovation[41]. - The company is focused on continuous product innovation and technical breakthroughs in the orthopedic implant medical device field, emphasizing the importance of R&D investment[51]. Market Position and Strategy - The company maintains a leading market position in the orthopedic implant medical device sector, with a strong competitive edge against foreign enterprises[38]. - The orthopedic implant medical device market in China grew from 16.4 billion yuan in 2015 to 30.8 billion yuan in 2019, with a compound annual growth rate of 17.03%[29]. - The company continues to expand its product line, covering spinal, trauma, joint, and sports medicine segments[30]. - The company emphasizes collaboration with medical institutions and clinical doctors to enhance product innovation and market reach[34]. Risks and Challenges - The company has detailed the major risks and countermeasures it will face in the future within the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[4]. - The company faces risks related to new product development and market promotion, including potential failures in meeting regulatory standards[78]. - The ongoing COVID-19 pandemic poses risks to the company's operations, affecting customer and distributor activities, which may lead to reduced surgical volumes[81]. Corporate Governance - The board of directors confirmed that all members attended the board meeting, ensuring the authenticity and completeness of the semi-annual report[4]. - The semi-annual report has not been audited, but the responsible persons have declared the financial report's authenticity and completeness[4]. - The company has not made any special arrangements for corporate governance during this reporting period[4]. - There are ongoing commitments to reduce related party transactions to enhance corporate governance[115]. Shareholder Commitments and Profit Distribution - The company has a profit distribution policy in place, with commitments to ensure transparency and accountability[112]. - The profit distribution policy emphasizes cash dividends, with a minimum cash dividend ratio of 80% for mature companies without major capital expenditures[176]. - The company will ensure that the profit distribution plan is executed within two months after the shareholders' meeting resolution[176]. - The company commits to compensating investors for losses caused by false statements in the prospectus[149]. Environmental and Social Responsibility - The company has not experienced any significant environmental incidents or penalties during the reporting period, adhering to environmental protection laws and regulations[104]. - The company has implemented strict internal environmental management standards, ensuring pollutant emissions comply with relevant standards[104]. - The company has not reported any measures taken to reduce carbon emissions during the reporting period[108].

Financial Performance - The company's operating revenue for Q1 2022 was ¥339,787,138.24, representing a decrease of 19.31% compared to the same period last year[6]. - The net profit attributable to shareholders for Q1 2022 was ¥97,884,290.18, down 11.99% year-on-year[6]. - The basic earnings per share for Q1 2022 was ¥0.24, reflecting a decline of 22.58% compared to the previous year[6]. - The weighted average return on equity was 2.14%, a decrease of 2.29 percentage points from the previous year[6]. - The company's net profit for the current period is CNY 97,839,105.81, a decrease of 12.1% compared to CNY 111,438,989.98 in the previous period[23]. - Operating profit for the current period is CNY 113,975,894.14, down 12.2% from CNY 129,805,878.02 in the previous period[23]. - The total revenue from sales of goods and services received cash of CNY 452,337,106.36, an increase of 4.9% compared to CNY 432,096,414.51 in the previous period[25]. - The basic earnings per share decreased to CNY 0.24 from CNY 0.31, reflecting a decline of 22.6%[25]. Cash Flow and Assets - The net cash flow from operating activities increased by 84.56% to ¥117,419,230.70, primarily due to a reduction in payments for imported raw materials[6][8]. - Cash and cash equivalents as of March 31, 2022, amounted to RMB 2,661,766,876.36, an increase of 4.0% from RMB 2,559,516,190.32 at the end of 2021[17]. - The cash and cash equivalents at the end of the period reached CNY 2,661,766,876.36, up from CNY 1,652,855,224.62, indicating a growth of 61.6%[27]. - The company experienced a net increase in cash and cash equivalents of CNY 102,250,686.04, compared to CNY 51,479,034.04 in the previous period, indicating a positive cash flow trend[27]. - The total assets at the end of the reporting period were ¥5,500,016,576.82, an increase of 1.79% from the end of the previous year[8]. - Total assets as of March 31, 2022, were RMB 5,500,016,576.82, compared to RMB 5,403,274,095.25 at the end of 2021, marking an increase of 1.8%[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,932[9]. - The largest shareholder, Shandong Weigao Group Medical Polymer Company, held 50.63% of the shares[11]. Research and Development - The company's R&D investment totaled ¥18,820,083.16, a decrease of 22.15% year-on-year, with R&D expenses accounting for 5.54% of operating revenue, down 0.20 percentage points[6][8]. - Research and development expenses decreased to CNY 18,820,083.16 from CNY 24,176,004.26, reflecting a reduction of 22.1%[23]. Operational Challenges - The company faced supply chain disruptions due to COVID-19 restrictions in March 2022, impacting product availability[15]. - The company resumed normal operations in early April 2022 after the local COVID-19 situation was brought under control[15]. - The company is actively participating in volume-based procurement initiatives across multiple provinces, which began implementation in March 2022[15]. Financial Adjustments and Compliance - The company announced the implementation of new accounting standards starting from 2022[29]. - The financial statements for the year of first-time application were adjusted accordingly[29]. - The announcement was made by the board of directors on April 29, 2022[29]. - The accounting work is overseen by Xin Wenzhi, who is also the head of the accounting institution[29]. - Gong Jianbo is the company leader responsible for the announcement[29]. - The company did not apply the new accounting standards for the current reporting period[29]. - The adjustments pertain to the financial statements at the beginning of the year[29]. - The announcement is part of the company's compliance with regulatory requirements[29]. - The board of directors is committed to transparency in financial reporting[29]. - The company aims to enhance its financial reporting quality through these adjustments[29].

Financial Performance - The company's operating revenue for 2021 was approximately RMB 2.15 billion, an increase of 18.08% compared to RMB 1.82 billion in 2020[24]. - The net profit attributable to shareholders for 2021 was approximately RMB 690.32 million, reflecting a growth of 23.62% from RMB 558.40 million in the previous year[24]. - The net cash flow from operating activities reached approximately RMB 788.25 million, up 22.38% from RMB 644.12 million in 2020[26]. - The company's total assets as of the end of 2021 were approximately RMB 5.40 billion, a 70.20% increase from RMB 3.17 billion at the end of 2020[26]. - The net assets attributable to shareholders increased by 84.67% to approximately RMB 4.53 billion from RMB 2.45 billion in 2020[26]. - Basic earnings per share for 2021 were RMB 1.82, a 16.67% increase from RMB 1.56 in 2020[26]. - The overall gross profit margin for the reporting period was 81.17%[35]. - The company's operating revenue for the reporting period was CNY 2,153.55 million, representing an 18.08% year-on-year increase[98]. - Operating costs increased to CNY 405.42 million, a rise of 26.01% compared to the previous year, primarily due to the recovery of medical institutions and an increase in surgical volumes[99]. - The gross margin for the orthopedic medical device manufacturing segment was 81.23%, a decrease of 1.15 percentage points from the previous year[105]. Research and Development - The company's R&D investment as a percentage of operating revenue rose to 5.63%, an increase of 1.11 percentage points from 4.52% in 2020[26]. - The total R&D investment for the current year is CNY 121,225,000.04, a significant increase of 47% compared to CNY 82,463,200.84 from the previous year[66]. - Research and development expenses reached CNY 121.23 million, up 47.00% year-on-year, reflecting the company's commitment to innovation and product development[98]. - The company has filed 63 new patent applications this year, with 62 patents granted, bringing the total to 355 applications and 268 granted patents[65]. - The company focuses on continuous product innovation and has strengthened R&D investment to meet diverse clinical needs in orthopedic surgery[65]. - The company has developed several core technologies, including hook-shaped trapezoidal thread technology and new embedded saddle-shaped pressure ring technology, covering various orthopedic implant fields[44]. Market Position and Strategy - The company ranks first among domestic manufacturers and fifth overall in the orthopedic implant medical device market, with specific market shares of first in spinal products and second in trauma products[50]. - The orthopedic medical device industry in China is experiencing rapid growth, driven by an aging population and increasing health awareness, presenting substantial market opportunities[49]. - The company aims to strengthen its brand competitiveness and profitability by expanding its product line with new technologies and materials[51]. - The company is actively responding to national policies on centralized procurement, establishing a specialized sales team to enhance market share[50]. - The company maintains a multi-brand strategy and focuses on expanding sales channels and developing secondary hospitals[36]. Corporate Governance - The company has not yet achieved profitability since its listing[3]. - The company has received a standard unqualified audit report from Da Hua Certified Public Accountants[4]. - The management has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company does not have any special arrangements for corporate governance[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring clear responsibilities and effective coordination among its governing bodies[144]. Dividend Policy - The company plans to distribute a cash dividend of 5.20 CNY per 10 shares, totaling 20,800,000 CNY, which represents 30.13% of the net profit attributable to shareholders for the year 2021[5]. - The cash dividend policy stipulates that in the absence of significant capital expenditure, at least 80% of profits should be distributed as cash dividends during the mature phase of development[185]. - The company aims to maintain a continuous and stable profit distribution policy, with a minimum of 10% of the distributable profit allocated as cash dividends each year[186]. Risks and Challenges - The company has detailed the major risks it will face in the future and the corresponding countermeasures in the report[3]. - The forward-looking statements in the report do not constitute substantial commitments to investors[6]. - The company maintains a high gross profit margin, but may face risks of declining product prices due to national volume-based procurement policies, potentially impacting future profitability[90]. - The company faces risks related to product development, including potential failures in meeting regulatory standards and market demands[88]. Social Responsibility and ESG - The company actively participates in social welfare activities and has contributed to disaster relief efforts, including sending aid to Zhengzhou during the July 2021 floods[198]. - The company emphasizes ESG (Environmental, Social, and Governance) practices, integrating them into daily operations and promoting sustainable development[197]. - The company has not been classified as a key pollutant discharge unit by environmental protection authorities[199]. - There were no administrative penalties imposed on the company due to environmental issues during the reporting period[199].

| --- | --- | |----------------------------------------------------------------------------------------------------------|-------| | | | | 股票代码: 688161 山东威高骨科材料股份有限公司 SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD 2021年年度报告 | | | WEGO ORTHO 町島智科 | | 2021 年年度报告 重要提示 | --- | --- | |---------------------------------------------------------------------------------------|-------| | | | | 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | 二、 公司上市时未盈利且尚未实现盈利 | | | □是 √否 | | ...

证券代码：688161 证券简称：威高骨科 公告编号：2021-009 山东威高骨科材料股份有限公司 关于参加山东辖区上市公司 2021 年度投资者网上集 体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与广大投资者特别是中小投资者的沟通交流，构建和谐稳定的 投资者关系，切实提高公司透明度和管理水平，山东威高骨科材料股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会联合举办并由深 圳市全景网络有限公司承办的"山东辖区上市公司 2021 年度投资者网上集体接 待日活动"，现将有关事项公告如下： 一、 召开时间和形式 （一） 召开时间：2021 年 11 月 16 日 14:00-16:00 （二） 召开形式：本次集体接待日活动将采取网络在线交流形式举行，投 资者可以登录"全景·路演天下"（http://rs.p5w.net）参与本次活动。 二、 参加人员 公司董事会秘书、财务负责人辛文智先生将参与本次投资者网上集体接待日 活动，与投资者进行在线交流，欢迎广大投资者积极参与。 ...